NCT03550729

Brief Summary

The role of physical training in the treatment of pulmonary arterial hypertension (PAH) is controversial. The aim of the project is to evaluate the effect of physical training on markers of endothelial function and integrity and to identify those biomarkers associated with a better therapeutic response in patients with PAH and in an experimental model of pulmonary hypertension. Methodology: 1) Study in humans: sample size will be 50 patients with PAH. Responders and non-responders will be identified for a 12-week resistance training program. Before and after the physical training program, endothelial microparticles and circulating vascular progenitor cells, and metabolomic and mitochondrial function parameters in circulating endothelial cells will be analyzed. Patients will be identified in whom a more favorable response to the training program is obtained. Additionally, investigators will evaluate the relationship between this response and the biomarkers both at baseline and their change with the training program. 2) Study in a murine experimental model: investigators will study mice with pulmonary hypertension induced by the administration of Semaxanib (SU5416) and exposure to hypoxia for 3 weeks and control mice. Half of them will exercise on a treadmill for 3 weeks. At the end of the program the right ventricular pressure will be measured and the animals will be sacrificed. Morphometric studies in pulmonary and cardiac tissue, pulmonary endothelial function and metabolomic parameters in cardiac and skeletal muscle will be performed. Differences in these variables between the different experimental groups will be analyzed.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 25, 2018

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 8, 2018

Completed
23 days until next milestone

Study Start

First participant enrolled

July 1, 2018

Completed
5.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2024

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

April 22, 2024

Status Verified

April 1, 2024

Enrollment Period

5.8 years

First QC Date

May 25, 2018

Last Update Submit

April 19, 2024

Conditions

Keywords

Exercise trainingBiomarkers

Outcome Measures

Primary Outcomes (1)

  • Endurance time

    Baseline - 12 weeks

Study Arms (1)

Training

EXPERIMENTAL

12-weeks of supervised endurance training program.

Behavioral: Endurance training

Interventions

Endurance training 3 times per week during 3 months using interval training above 70% of load peak reached in the incremental exercise test. The duration of the sessions will be adapted individually to each patient (approximately 60 minutes).

Training

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age over 18 years
  • Functional class of New York Heart Association (NYHA) II-III
  • Diagnosis of pulmonary hypertension (PH) by right heart catheterization, as follows:
  • Mean pulmonary arterial pressure (mPAP) \>=25 mmHg
  • Pulmonary vascular resistance (PVR) ≥240 din / s / cm5
  • Pulmonary interlock pressure (PCWP) ≤15 mmHg
  • Patients with optimized PAH treatment, including intensified treatment with diuretics and who have remained stable for at least 2 months before entering the study (changes in medical treatment are not expected during the entire 12-week study period)
  • Be able to understand and be willing to sign the informed consent form

You may not qualify if:

  • Other type of PH (groups 2, 3, 4 or 5)
  • Pregnant women
  • Disability to exercise on a cycle ergometer or walk
  • Acute infection or fever
  • Any change in the treatment of the disease in the last 2 months
  • Acute ischemic heart disease, unstable angina pectoris, exercise-induced ventricular arrhythmias, decompensated heart failure
  • History or suspicion of inability to cooperate adequately in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Clínic

Barcelona, 08036, Spain

Location

MeSH Terms

Conditions

Pulmonary Arterial Hypertension

Interventions

Endurance Training

Condition Hierarchy (Ancestors)

Hypertension, PulmonaryLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Exercise TherapyRehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsPhysical Therapy ModalitiesPhysical Conditioning, HumanExerciseMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior specialist in Pneumology

Study Record Dates

First Submitted

May 25, 2018

First Posted

June 8, 2018

Study Start

July 1, 2018

Primary Completion

May 1, 2024

Study Completion

December 1, 2024

Last Updated

April 22, 2024

Record last verified: 2024-04

Locations